2022
Clinical utility of MR/ultrasound fusion-guided biopsy in patients with lower suspicion lesions on active surveillance for low-risk prostate cancer
Lokeshwar SD, Nguyen J, Rahman SN, Khajir G, Ho R, Ghabili K, Leapman MS, Weinreb JC, Sprenkle PC. Clinical utility of MR/ultrasound fusion-guided biopsy in patients with lower suspicion lesions on active surveillance for low-risk prostate cancer. Urologic Oncology Seminars And Original Investigations 2022, 40: 407.e21-407.e27. PMID: 35811206, DOI: 10.1016/j.urolonc.2022.06.005.Peer-Reviewed Original ResearchConceptsActive surveillanceIndex lesionProstate biopsyProstate cancerMultiparametric magnetic resonance imagingData System version 2Low-risk CaPSurveillance prostate biopsyGleason grade groupMultivariate logistic regressionSignificant prostate cancerProstate Imaging ReportingReceiver operator characteristic curvePI-RADS 2Low-suspicion lesionsOperator characteristic curveMagnetic resonance imagingHigher PSADOnly significant variablePrimary outcomeMultivariable analysisSystematic biopsyRetrospective analysisBiopsy approachImaging Reporting
2019
PD11-11 DECIPHER BIOPSY GENOMIC TEST RELATED TO GLEASON GRADE GROUP INDEPENDENT OF PROSTATE IMAGING REPORTING AND DATA SYSTEM VERSION 2
Martin D, Ghabili* K, Levi A, Humphrey P, Schulam P, Sprenkle P. PD11-11 DECIPHER BIOPSY GENOMIC TEST RELATED TO GLEASON GRADE GROUP INDEPENDENT OF PROSTATE IMAGING REPORTING AND DATA SYSTEM VERSION 2. Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000555367.28091.c8.Peer-Reviewed Original Research
2018
Role of core location in targeted MRI-ultrasound fusion biopsy of prostate lesions.
Lu A, Ghabili K, Nguyen K, Sprenkle P. Role of core location in targeted MRI-ultrasound fusion biopsy of prostate lesions. Journal Of Clinical Oncology 2018, 36: 136-136. DOI: 10.1200/jco.2018.36.6_suppl.136.Peer-Reviewed Original ResearchCancer detection rateFusion biopsyProstate lesionsSignificant cancerProstate cancerSignificant cancer detection rateMRI-US fusion biopsyHigher PIRADS scoresHigh Gleason scoreSignificant prostate cancerMRI-ultrasound fusion biopsyProstate Imaging ReportingClinical suspicionGleason scorePIRADS scoreBiopsy histologyTemplate biopsyDetection rateLesion volumePathology gradeBiopsy coresMultiparametric MRILesion basisBiopsyImaging ReportingIs PI-RADS 3/total lesion ratio associated with clinically-significant prostate cancer in patients with equivocal-risk lesions on multi-parametric MRI?
Ghabili K, Swallow M, Suarez-Sarmiento A, Syed J, Leapman M, Weinreb J, Sprenkle P. Is PI-RADS 3/total lesion ratio associated with clinically-significant prostate cancer in patients with equivocal-risk lesions on multi-parametric MRI? Journal Of Clinical Oncology 2018, 36: 149-149. DOI: 10.1200/jco.2018.36.6_suppl.149.Peer-Reviewed Original ResearchSmaller prostate volumeMulti-parametric MRISignificant prostate cancerProstate volumeProstate cancerROI ratioPSA densityGrade groupPrediction of csPCaRisk of csPCaData System (BI-RADS) category 3Prostate Imaging ReportingMpMRI findingsBiopsy databasePrior diagnosisTargeted biopsiesFusion biopsyPositive coresCsPCaUnnecessary biopsiesBiopsyMultivariate analysisPatientsImaging ReportingLesions